losartan-hydrochlorothiazide

losartan-hydrochlorothiazide

Hyzaar® An antihypertensive with an angiotensin II receptor antagonist and a diuretic
References in periodicals archive ?
Preliminary analysis of products from these companies intercepted on their way to the United States identified counterfeit versions of these prescription drugs: the cholesterol-lowering agents Lipitor (atorvastatin), Crestor (rosuvastatin), and Zetia (ezetimibe); the antihypertensives Diovan (valsartan) and Hyzaar (losartan-hydrochlorothiazide); Actonel (risedronate), a bisphosphonate for osteoporosis; Nexium (esomeprazole) for gastroesophageal reflux disease; Celebrex (celecoxib) for arthritis-related pain; Arimidex (anastrozole) for breast cancer; and Propecia (finasteride), for male pattern baldness.
Preliminary results of laboratory analyses for products from these companies intercepted on their way to the United States have identified counterfeit versions of the following prescription drugs: the cholesterol-lowering agents Lipitor (atorvastatin), Crestor (rosuvastatin), and Zetia (ezetimibe); the antihypertensives Diovan (valsartan) and Hyzaar (losartan-hydrochlorothiazide); Actonel (risedronate), a bisphosphonate for osteoporosis; Nexium (esomeprazole) for gastroesophageal reflux disease; Celebrex (celecoxib) for arthritis-related pain; Arimidex (anastrozole) for breast cancer; and Propecia (finasteride), for male pattern baldness.
Preliminary results of laboratory analyses for products from these companies intercepted on their way to the United States have identified counterfeit versions of the fbllowing prescription drugs: the cholesterol-lowering agents Lipitor (atorvastatin), Crestor (rosuvastatin), and Zetia (ezetimibe); the antihypertensives Diovan (valsartan) and Hyzaar (losartan-hydrochlorothiazide); Actonel (risedronate), a bisphosphonate for osteoporosis; Nexium (esomeprazole) for gastroesophageal reflux disease; Celebrex (celecoxib) for arthritis-related pain; Arimidex (anastrozole) for breast cancer; and Propecia (finasteride), for male pattern baldness.
Those on the losartan-hydrochlorothiazide combination had an initial mean systolic reduction of 6 mm Hg, which increased to 14 mm Hg at week 8 and 16 mm Hg by the close of the treatment period.